Drugs / HL217
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03648346 | Apr → Jul 2018 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03650608 | Aug 2016 → Aug 2017 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL217 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03648346 ↗ |